V-Wave Ltd. said on Dec. 17 that it has closed all remaining tranches of a $98 million extended series C financing led by Deerfield Management. The funds will be used to complete a pivotal IDE trial for its Ventura interatrial shunt system for the treatment of advanced heart failure (HF) and submit a PMA to the FDA for U.S. marketing approval.
LONDON – Metabolic diseases specialist Northsea Therapeutics BV closed a $80 million series C to fund phase II development in two further indications, as it awaits the final results from the phase IIb trial of its lead product, icosabutate, in the treatment of nonalcoholic steatohepatitis (NASH), which are due at the start of 2023.
PARIS – Dyameo SAS has successfully raised $1.13 million in seed funding to develop its endoscopy probe used for the instantaneous detection of cancerous cells. This round was led by Medevice SAS and Aquiti Gestion SAS via its co-investment fund, NACO.
Depixus Ltd. has raised $35.4 million in an oversubscribed series A financing to push commercialization of its Magna multiomics system. The series A round was co-led by Lansdowne Partners and PSIM Fund, with participation from Casdin Capital and existing investor Arix Bioscience. The funds bring the company's total equity and grant funding to more than $47 million.
Anheart Therapeutics Co. Ltd. raised $61 million in a series B round to support the development of a slate of precision oncology pipeline in-licensed by the company from Daiichi Sankyo Co. Ltd. Toward that end, funds will support phase II testing of the Hangzhou, China-based firm’s lead asset, the ROS1 inhibitor taletrectinib, for the potential treatment of non-small-cell lung cancer.
There are many companies using artificial intelligence to aid drug development, with a seemingly overwhelming number of “world firsts” being claimed in this quickly evolving field. After signing a three-year neurology drug development deal with Eli Lilly and Co. worth up to $706 million in July, Verge Genomics is also making waves and just raised $98 million in series B financing to support development of its own AI drug development technology.
DUBLIN – Anaveon AG raised CHF110 million (US$119.5 million) in a series B round to accelerate development of its interleukin-2 (IL-2) agonist ANV-419, which is currently undergoing a phase I/II trial. “We are putting our compound into multiple clinical trials and multiple indications in parallel,” CEO and co-founder Andreas Katopodis told BioWorld.
RSS
